Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 30 April | 16:44:33 Europe / Stockholm

Svenska | English

BioStock

BioInvent International AB: BioStock: Takedas milstolpsbetalning stärker BioInvents affärsmodell

2025-04-09 13:13:05

BioInvent is reinforcing its position as a partner in antibody development. This was made evident as global pharmaceutical giant Takeda has initiated a phase III trial with mezagitamab (TAK-079) - an antibody originally identified using BioInvent's proprietary n-CoDeR platform. As a result, a milestone payment of USD 1 million to BioInvent has been triggered.

Läs hela artikeln på biostock.se:

https://www.biostock.se/2025/04/takedas-milstolpsbetalning-starker-bioinvents-affarsmodell/

Detta är ett pressmeddelande från BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden